CEBP Infection and Cancer: Biology, Therapeutics, and Prevention Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kato, I.
Right arrow Articles by Chyou, P. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kato, I.
Right arrow Articles by Chyou, P. H.

Cancer Epidemiology Biomarkers & Prevention, Vol 1, Issue 1 51-55, Copyright © 1991 by American Association for Cancer Research


ARTICLES

Prediagnostic hematocrit values and subsequent cancer risk

I Kato, A Nomura, GN Stemmermann and PH Chyou
Japan-Hawaii Cancer Study, Kuakini Medical Center, Honolulu 96817.

In this prospective study, the association between hematocrit values measured in 1965-68 and subsequent cancer incidence was studied among 7737 Japanese-American men in Hawaii. With an increase in hematocrit levels, there was an increasing risk for lung cancer, especially squamous or small cell type, and for kidney cancer. However, a statistically significant trend remained only for kidney cancer after adjusting for smoking history. The relative risk for kidney cancer was 4.94 (95% confidence interval, 1.03-23.63) for subjects with hematocrit values of 47 or higher compared with those with hematocrit values of 43 or lower. In contrast, the risk of oral-pharyngeal cancer decreased with increasing hematocrit levels. With adjustment for cigarette smoking and alcohol intake, the relative risk for oral-pharyngeal cancer was 0.20 (95% confidence interval, 0.04-0.88) for subjects with hematocrit values of 47 or higher compared with those with hematocrit values of 43 or lower. The association with kidney or oral-pharyngeal cancer was not affected by the time interval between examination and diagnosis of these cancers (< or = 10 and > 10 years). Erythropoietin production by kidney tumors and micronutrient deficiencies in oral-pharyngeal cancer cases may partially account for these results.





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
Copyright © 1991 by the American Association for Cancer Research.